Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2020 Sep;9(5):479-490. doi: 10.1159/000509554. Epub 2020 Aug 20.
Abstract
摘要
相似文献
1
Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.钆塞酸二钠增强磁共振成像可预测肝细胞癌中WNT/β-连环蛋白突变及对免疫检查点抑制剂治疗的耐药性。
Liver Cancer. 2020 Sep;9(5):479-490. doi: 10.1159/000509554. Epub 2020 Aug 20.
2
OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.OATP1B3 表达与 Wnt/β-连环蛋白信号通路密切相关，是肝癌中钆塞酸的转运体。
J Hepatol. 2014 Nov;61(5):1080-7. doi: 10.1016/j.jhep.2014.06.008. Epub 2014 Jun 16.
3
Evaluation of combined Gd-EOB-DTPA and gadobutrol magnetic resonance imaging for the prediction of hepatocellular carcinoma grading.钆塞酸二钠与钆布醇联合磁共振成像用于预测肝细胞癌分级的评估
Acta Radiol. 2016 Aug;57(8):932-8. doi: 10.1177/0284185115616293. Epub 2015 Nov 18.
4
Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma.非酒精性脂肪性肝病诱导的肝细胞癌中肝脏氧化应激相关因素与Wnt/β-连环蛋白信号通路激活之间的关联
Cancers (Basel). 2022 Apr 20;14(9):2066. doi: 10.3390/cancers14092066.
5
Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea.钆塞酸二钠增强磁共振成像（Gd-EOB-DTPA MRI）与肝细胞特异性对比剂增强磁共振成像（ECCM-MRI）及多排螺旋计算机断层扫描在泰国和韩国疑似肝细胞癌患者中的卫生经济学评价
J Med Econ. 2016 Aug;19(8):759-68. doi: 10.3111/13696998.2016.1171230. Epub 2016 Apr 27.
6
OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.OATPB1/B3 和 MRP3 在肝细胞腺瘤中的表达可预测 Gd-EOB-DTPA 摄取，与恶性风险相关。
Liver Int. 2019 Jan;39(1):158-167. doi: 10.1111/liv.13964. Epub 2018 Oct 8.
7
Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China.钆塞酸二钠增强磁共振成像与肝细胞特异性对比剂增强磁共振成像及多排螺旋CT在中国肝细胞癌诊断中的卫生经济学评估
PLoS One. 2018 Jan 11;13(1):e0191095. doi: 10.1371/journal.pone.0191095. eCollection 2018.
8
Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.钆塞酸二钠增强磁共振成像在诊断小肝细胞癌方面优于多排螺旋 CT：一项荟萃分析。
Liver Transpl. 2017 Dec;23(12):1505-1518. doi: 10.1002/lt.24867.
9
Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.钆塞酸二钠增强 MRI 比多排 CT 在肝癌根治性治疗决策中的作用更好。
Ann Surg Oncol. 2013 Sep;20(9):2893-900. doi: 10.1245/s10434-013-3001-y. Epub 2013 May 7.
10
Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.肝细胞癌在对比增强计算机断层扫描、钆喷酸葡胺增强磁共振成像和钆塞酸二钠增强磁共振成像上的个体内影像特征比较
Acta Radiol. 2018 Jun;59(6):639-648. doi: 10.1177/0284185117728534. Epub 2017 Aug 20.
引用本文的文献
1
MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma.用于肝细胞癌预后评估的MRI成像生物标志物
J Korean Soc Radiol. 2025 May;86(3):364-380. doi: 10.3348/jksr.2025.0029. Epub 2025 May 28.
2
The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors.正常肝胆细胞区域化程序对原发性肝肿瘤表型和功能的影响。
Liver Cancer. 2024 Aug 26;14(1):92-103. doi: 10.1159/000541077. eCollection 2025 Mar.
3
Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl-Diethylenetriaminepentaacetic Acid MRI.利用肝胆期钆塞酸二钠磁共振成像预测阿替利珠单抗/贝伐单抗治疗不可切除肝细胞癌的疗效
Cancers (Basel). 2024 Jun 19;16(12):2275. doi: 10.3390/cancers16122275.
4
Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.具有Wnt/β-连环蛋白突变的人类肝细胞癌免疫微环境的两个不同特征
Liver Cancer. 2023 Oct 9;13(3):285-305. doi: 10.1159/000533818. eCollection 2024 Jun.
5
Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma.肿瘤微环境中的癌细胞遗传学塑造揭示了肝癌中以髓样细胞为中心的可利用脆弱性。
Nat Commun. 2024 Mar 22;15(1):2581. doi: 10.1038/s41467-024-46835-2.
6
Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.联合免疫疗法及抗程序性细胞死亡蛋白1/程序性死亡配体1单药疗法治疗不可切除肝细胞癌时超进展性疾病的发生率
Liver Cancer. 2023 May 11;13(1):56-69. doi: 10.1159/000531024. eCollection 2024 Feb.
7
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.不可切除肝细胞癌中经动脉化疗栓塞联合仑伐替尼，以及联合与不联合 PD-1 抑制剂的预后列线图模型。
Br J Radiol. 2024 Feb 28;97(1155):668-679. doi: 10.1093/bjr/tqae018.
8
The Era of Immunotherapy in Hepatocellular Carcinoma: The New Mission and Challenges of Magnetic Resonance Imaging.肝细胞癌免疫治疗时代：磁共振成像的新使命与挑战
Cancers (Basel). 2023 Sep 22;15(19):4677. doi: 10.3390/cancers15194677.
9
Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.钆塞酸二钠增强MRI成像的肝胆期与免疫微环境及阿替利珠单抗联合贝伐单抗治疗反应的相关性
Cancers (Basel). 2023 Aug 24;15(17):4234. doi: 10.3390/cancers15174234.
10
Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence.一名90岁肝细胞癌复发患者接受阿替利珠单抗联合贝伐单抗治疗，多学科治疗成功且完全缓解。
Int Cancer Conf J. 2023 Jun 23;12(4):274-278. doi: 10.1007/s13691-023-00618-6. eCollection 2023 Oct.
本文引用的文献
1
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.肝细胞癌的遗传和免疫背景与程序性细胞死亡蛋白-1表达之间的关联
Liver Cancer. 2020 Aug;9(4):426-439. doi: 10.1159/000506352. Epub 2020 Mar 17.
2
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
3
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
4
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.肝细胞癌全身治疗的新时代：阿替利珠单抗联合贝伐珠单抗联合疗法。
Liver Cancer. 2020 Apr;9(2):119-137. doi: 10.1159/000505189. Epub 2020 Mar 5.
5
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.晚期肝细胞癌中PD-1/PD-L1抗体与VEGF抑制剂联合免疫治疗的科学依据
Cancers (Basel). 2020 Apr 27;12(5):1089. doi: 10.3390/cancers12051089.
6
Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma.精准病理学分析肝癌的发生发展：对肝癌精准诊断的启示。
Pathol Int. 2020 Mar;70(3):140-154. doi: 10.1111/pin.12895. Epub 2020 Jan 6.
7
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
8
Systemic Treatment for Advanced Hepatocellular Carcinoma.晚期肝细胞癌的全身治疗
Liver Cancer. 2019 Oct;8(5):341-358. doi: 10.1159/000496439. Epub 2019 Mar 6.
9
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.肝细胞癌的免疫肿瘤学疗法：现状与正在进行的试验
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.
10
Molecular and histological correlations in liver cancer.肝癌的分子和组织学相关性。
J Hepatol. 2019 Sep;71(3):616-630. doi: 10.1016/j.jhep.2019.06.001. Epub 2019 Jun 10.
Zotero 插件